Loading stock data…
CDT
$0.74-0.03 (-4.26%)
After Hours$0.78+0.03 (+4.56%)· Last close Jun 9
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CDT Equity Inc. in the Healthcare sector is trading at $0.74. The stock is currently near its 52-week low of $0.69, remaining 98.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.74
Potential Downside
0%
Whystock Fair Value$0.74
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has co...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
547.06%
Volume
Today's trading volume
206,328
Recent News
CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. AstraZeneca PLC is among the best cancer stocks on this list. TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent […]
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.5% and the S